SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ALTH Analysis & Videos »
ALTH: Bull or Bear?
FDA Calendar Updates: KG, PTIE, DRRX, ALTH, TRIB, CBST, DYAX
ALTH
|
|
|
-19.15%
in
152 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 243 entries as of 7/7/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
|
Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await
ALTH
|
|
|
+9.00%
in
14 days
(closed on 07/07/09)
<> Since I first wrote about Lixte Biotech (OTC:LIXT) at <font> BioMedReports.com in early April </font> , the Company has provided an update on its development-stage cancer drug discovery operations as part of a SEC 10Q filing in mid-May for 1Q09. LIXT.OB was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery research that is primarily focused on the development of compounds for malignancies with few effective treatment options – such as certain types of brain cancer<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO
ALTH
|
|
|
+0.69%
in
23 days
(closed on 06/23/09)
<> Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete respon...
|
Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches
ALTH
|
|
|
+13.75%
in
14 days
(closed on 05/31/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
Allos Therapeutics: Small-Cap Cancer Biotech with FDA Catalyst
ALTH
|
|
|
+13.27%
in
20 days
(closed on 05/17/09)
Allos Therapeutics (ALTH) is small-cap cancer biotech which filed a NDA on 3/25/09 for pralatrexate (PDX) in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). ALTH requested priority (six-month) review for the application, with an expected 60-day period for the FDA to accept the filing and rule on priority review status. <> The priority review PDUFA date would be 9/25/09 (versus 1/25/10 for standard, 10-month review). PTCL comprises a biologically diverse group of blood-based cancers that typically have a worse progno...
|
FDA, Clinical Trial Calendar Updates: THOR, ALTH
ALTH
|
|
|
-11.16%
in
7 days
(closed on 04/27/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
FDA and Clinical Trial Calendar Updates
ALTH
|
|
|
-9.40%
in
26 days
(closed on 04/20/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 106 entries through 3/25/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Allos Therapeutics Inc.
ALTH
|
|
|
-19.25%
in
508 days
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule therapeutics for the treatment of cancer. Its lead product candidate, PDX (pralatrexate), is a novel antifolate under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. Its other product candidate is RH1, a targeted chemotherapeutic agent, under evaluation in Phase 1 in patients with advanced sol...
|
People Bullish on ALTH
People Bearish on ALTH
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ALTH |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Allos Therapeutics Inc.
- Answers.com
